The Multinational Association of Supportive Care in Cancer (MASCC) shared on LinkedIn:
“Cognitive impairment remains a priority concern by people both during and after cancer treatment.
But a major barrier to the provision of proactive supportive care in this context is that cognitive impairment is highly unpredictable.
In this episode of the Supportive Care Digest, Dr Courtney Cross reviews a recent pilot study examining pre-treatment gut microbiome and salivary metabolome signatures and their association with chemotherapy-induced cognitive decline.”
Other articles about Supportive Care Digest and cognitive decline on OncoDaily.